We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Council on Drugs

JAMA. 1963;184(7):577-579. doi:10.1001/jama.1963.03700200099019.
Text Size: A A A
Published online


New Drugs and Developments in Therapeutics  Council on Drugs' Statements

Dydrogesterone (Duphaston) 

Summary of Council Opinion.  —Dydrogesterone (9β,10α-Pregna-4,6-diene-3,20-dione) is a synthetic progestogen derived from retro-progesterone. The alteration of steric configuration is believed to account for its pharmacological differences from progesterone and the other progestogens. Although the contradictory clinical evidence available from uncontrolled studies is inadequate to determine the extent to which dydrogesterone may be useful as an oral progestational agent, it appears to be nontoxic and without androgenic or estrogenic activity. No suppression of pituitary activity has been observed clinically.

Actions and Uses.  —See the statement on progesterone under "Ovarian Hormones" in New and Nonofficial Drugs, 1963. Clinical studies have shown that dydrogesterone produces a progestational reaction in the estrogen-primed endometrium, the degree of change being proportional to the dose. Withdrawal bleeding can be produced in the estrogen-primed endometrium, and in the absence of pregnancy. Dydrogesterone differs from other progestogens


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.